SRR27320692
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 83.41666667
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- INTERFERON_GAMMA_RESPONSE+0.680
- ALLOGRAFT_REJECTION+0.570
- INFLAMMATORY_RESPONSE+0.480
- IL6_JAK_STAT3_SIGNALING+0.450
- E2F_TARGETS+0.430
- MYC_TARGETS_V2+0.420
- G2M_CHECKPOINT+0.390
- COMPLEMENT+0.360
- TNFA_SIGNALING_VIA_NFKB+0.360
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.240
- MYOGENESIS-0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
- DNA_REPAIR-0.150
- CHOLESTEROL_HOMEOSTASIS-0.140
- KRAS_SIGNALING_DN-0.140
- ANDROGEN_RESPONSE-0.130
- PANCREAS_BETA_CELLS-0.110
- HYPOXIA-0.100
- TGF_BETA_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG766 | — | — | 0.901 |
| 2 | TCGA-AR-A1AT-01A-11R-A12P-07 | — | C | 0.871 |
| 3 | TCGA-A8-A07U-01A-11R-A034-07 | — | D | 0.869 |
| 4 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.861 |
| 5 | BSR_16_0031_E2_S98 | — | C | 0.857 |
| 6 | 20080189.TNBC | — | E | 0.857 |
| 7 | BS_M7HCF7DW | high-grade glioma | — | 0.854 |
| 8 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.853 |
| 9 | TCGA-AR-A1AJ-01A-21R-A12P-07 | — | D | 0.847 |
| 10 | 20080305.TNBC | — | D | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.680 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |